Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
  • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/42—Oxazoles
  • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/425—Thiazoles
  • A61K31/426—1,3-Thiazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/4965—Non-condensed pyrazines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
  • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
  • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
  • C07D213/40—Acylated substituent nitrogen atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
  • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
  • C07D213/56—Amides
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/61—Halogen atoms or nitro radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/62—Oxygen or sulfur atoms
  • C07D213/63—One oxygen atom
  • C07D213/65—One oxygen atom attached in position 3 or 5
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/62—Oxygen or sulfur atoms
  • C07D213/63—One oxygen atom
  • C07D213/68—One oxygen atom attached in position 4
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
  • C07D213/81—Amides; Imides
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
  • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
  • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
  • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
  • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
  • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
  • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
  • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
  • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
  • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
  • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
  • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
  • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
  • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
  • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
  • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
  • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
  • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
  • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
  • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
  • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
  • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
  • C07D277/28—Radicals substituted by nitrogen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
  • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
  • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
  • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
  • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
  • C07D277/62—Benzothiazoles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
  • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
  • C07D277/62—Benzothiazoles
  • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
  • C07D285/01—Five-membered rings
  • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
  • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
  • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
  • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
  • C07D491/04—Ortho-condensed systems
  • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
  • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
  • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
  • C07D493/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/06—Dipeptides
  • C07K5/06008—Dipeptides with the first amino acid being neutral
  • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
  • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/06—Dipeptides
  • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/08—Tripeptides
  • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
  • Y02P20/00—Technologies relating to chemical industry
  • Y02P20/50—Improvements relating to the production of bulk chemicals
  • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

• R 1 is hydrogen, halogen, halogenated or unsubstituted C 1-3 alkyl or unsubstituted C 1-3 alkoxy.
• R 2 is hydrogen or C 1-8 alkyl.
• R 3 is hydrogen or CH 2 R 3a ;
• R 3a is selected from phenyl, ethyl, cyclohexyl, furyl, naphthyl or F-substituted phenyl.
• R 4 is selected from any of the following substituted or unsubstituted groups: C 1-4 alkyl, C 1-4 alkoxy, 3-7 membered saturated cycloalkyl, 4-6 membered saturated hetero Cyclic group, 5-6 membered aryl group, 5-6 membered azaaryl group, bridging ring group, naphthyl group, benzofuryl group, benzopyridyl group, or 5-6 membered saturated oxygen heterocyclic group aphenylene group;
• any two of R 4a , R 4b , R 4c , and R 4d are connected to form a halogenated or unsubstituted 3-6 membered saturated carbocycle or oxygen heterocycle.
• R 4 is a 4-6 membered saturated cycloalkyl group substituted with fluorine.
• R 4 is selected from any of the following substituted or unsubstituted groups: -CH 3 , -OCH 3 ,
• R 4 is selected from any of the following groups: -CH 3 , CF 3 , -OCH 3 , -OCF 3 , -OC(CH 3 ) 3 ,
• R 5a , R 5b , and R 5c are independently selected from hydrogen, ethynyl, hydroxyl, -CONH 2 , -CONHCH 3 , -N(CH 3 ) 2 , fluorine, methoxy, phenyl, methylsulfonyl, amino, Carboxyl, carbomethoxy, azaphenyl, or any two of R 5a , R 5b , and R 5c are connected to form a 3-6-membered saturated cycloalkyl group or a 5-6-membered saturated oxygen heterocyclic group;
• L 2 is None, or R a , R b substituted or unsubstituted
• M is fluorine, chlorine, methyl, methoxy or -CF 3 .
• formula II-Ae formula II-Af, formula II-Ag, formula II-Ah, formula II-Ai, formula II-A-i1, formula II-A-i2, formula II- Shown in A-i3, formula II-A-i4 or formula II-A-i5:
• U, V, U', V' are independently selected from hydrogen, C 1-3 alkyl or halogen, preferably hydrogen, methyl or chlorine; W is O or S.
• z is 1, 2 or 3; q is 0 or 1 .
• T 1 , T 2 , and T 3 are independently selected from hydrogen or halogen, and at least one of them is halogen.
• T is fluorine
• R 1 is chlorine or hydrogen.
• the present invention also provides the above-mentioned compound, or its pharmaceutically acceptable salt, or its stereoisomer, or its optical isomer, or its deuterated compound in the preparation of prevention and/or treatment of coronavirus-related diseases Uses in medicine.
• the above-mentioned drugs for preventing and/or treating coronavirus-related diseases are anti-coronavirus drugs.
• anti-coronavirus drugs are drugs that inhibit coronavirus-infected cells.
• the above-mentioned anti-coronavirus drug is a coronavirus protease inhibitor, preferably a coronavirus main protease inhibitor.
• coronavirus is SARS-CoV-2, SARS-CoV, MERS-CoV, HcoV-229E, HcoV-NL63, HcoV-HKU1 or HcoV-OC43, preferably SARS-CoV-2.
• the above-mentioned medicines for preventing and/or treating coronavirus-related diseases are medicines for preventing and/or treating novel coronavirus pneumonia COVID-19.
• coronavirus main protease inhibitor is a SARS-CoV-2M pro inhibitor.
• C a-b alkyl means any alkyl group containing "a" to "b" carbon atoms.
• C 1-8 alkyl refers to a linear or branched alkyl group containing 1-8 carbon atoms.
• substitution herein means that one, two or more hydrogen atoms in the molecule are replaced by other different atoms or molecules, including one, two or more substitutions on the same or different atoms in the molecule .
• Deuterated compound refers to a compound obtained by replacing one or more hydrogens in the compound with deuterium.
• “Pharmaceutically acceptable” means that a certain carrier, vehicle, diluent, excipient, and/or formed salt are generally chemically or physically compatible with other ingredients that make up a pharmaceutical dosage form, and physiologically compatible with the compatible with the receptor.
• Salt is an acidic and/or basic salt formed of a compound or its stereoisomer with an inorganic and/or organic acid and/or base, including zwitterionic salts (inner salts), and quaternary ammonium salts , such as alkylammonium salts. These salts may be obtained directly in the final isolation and purification of the compounds. It can also be obtained by mixing the compound, or its stereoisomer, with a certain amount of acid or base as appropriate (for example, equivalent). These salts may form precipitates in solution and be collected by filtration, or may be recovered after evaporation of the solvent, or may be obtained by freeze-drying after reaction in an aqueous medium.
• “Pharmaceutically acceptable salt” can be hydrochloride, sulfate, citrate, besylate, hydrobromide, hydrofluoride, phosphate, acetate, propionate, Succinate, oxalate, malate, succinate, fumarate, maleate, tartrate, or trifluoroacetate.
• Halogen is fluoro, chloro, bromo or iodo.
• Aryl refers to an all-carbon monocyclic or fused polycyclic (ie, rings sharing adjacent pairs of carbon atoms) group having a conjugated pi-electron system, eg, phenyl.
• the aryl group contains no heteroatoms such as nitrogen, oxygen, or sulfur, and the point of attachment to the parent must be on a ring carbon atom with a conjugated pi electron system.
• Aryl groups can be substituted or unsubstituted.
• the "5- to 6-membered aryl group” refers to an aryl group having 5 or 6 ring carbon atoms.
• Heteroaryl refers to a heteroaromatic group containing one to more heteroatoms.
• the heteroatoms referred to herein include oxygen, sulfur and nitrogen.
• the heteroaryl group can be optionally substituted or unsubstituted.
• “5-6 membered heteroaryl” refers to a heteroaryl group having 5 or 6 ring atoms.
• Cycloalkyl refers to a saturated or unsaturated cyclic hydrocarbon substituent.
• “3-8 membered saturated cycloalkyl” refers to a saturated cycloalkyl group having 3-8 ring carbon atoms.
• Heterocyclyl refers to a saturated or unsaturated cyclic hydrocarbon substituent; and the cyclic hydrocarbon bears at least one ring heteroatom (including but not limited to O, S or N).
• ring heteroatom including but not limited to O, S or N.
• 3- to 8-membered saturated heterocyclic group refers to a saturated heterocyclic group having 3-8 ring atoms.
• Oxygen heterocycle means that the heteroatom in the heterocycle is O and does not contain S and N. and so on.
• Bridged ring group refers to a polycyclic cycloalkyl group in which two rings share two adjacent carbon atoms.
• fused ring aryl refers to a polycyclic aromatic group in which two rings share two adjacent carbon atoms, such as naphthyl (ie, 6-membered aromatic ring and 6-membered aromatic ring, or benzene ring and acene ring) , anthracenyl, phenanthrenyl.
• “Fused heteroaromatic/fused heteroaryl” means a polycyclic aromatic ring/aromatic group containing at least one heteroatom (O, N, or S) in which two rings share two adjacent carbon atoms or heteroatoms.
• a 5-membered aromatic or heteroaromatic ring e.g. furan, thiophene, pyrrole, pyridine ring
• a 6-membered aromatic or heteroaromatic ring e.g.
• benzene pyridine, pyridazine, pyrimidine, pyrazine ring), such as indole, or 6-membered aromatic ring or heteroaromatic ring and 6-membered aromatic ring or heteroaryl ring, such as quinoline; or more than 2 combined rings, such as acridine.
• "Nitrogen-containing fused heteroaryl ring” means that at least one of the heteroatoms in the above “fused heteroaryl ring" is N.
• 5-6 membered saturated heterocyclic group and 5-6-membered aryl group refers to a group formed by sharing two adjacent carbon atoms or heteroatoms between "5-6-membered saturated heterocyclic ring" and "5-6-membered aromatic ring” group.
• CD3 means a methyl group substituted with 3 deuteriums.
• “Saturated heterocyclic ring” refers to a saturated ring formed by replacing at least one carbon atom in a saturated carbocyclic ring with O, N and/or S. "Oxyheterocyclic ring” refers to a ring formed by replacing at least one carbon atom in a carbocyclic ring with O.
• the experimental results show that the present invention provides a compound capable of effectively inhibiting the activity of the main protease M pro of the new coronavirus, which can effectively block the replication and transcription of the SARS-CoV-2 virus in patients, and inhibit the SARS-CoV-2 in cells. COV-2 infection, providing strong support for the fight against SARS-COV-2.
• the compound provided by the invention also has good in vivo safety and pharmacokinetics It has low cardiotoxicity and is not easy to induce acute arrhythmia or even sudden death after administration.
• the compound of the present invention has very good application prospects in the preparation of SARS-CoV-2 M pro inhibitors, anti-SARS-CoV-2 drugs, and drugs for preventing and/or treating novel coronavirus pneumonia.
• Figure 2 shows the enzymatic inhibitory activity of compound 275 on SARS-COV-2 MPro.
• Figure 3 shows the enzymatic inhibitory activity of compound 289 on SARS-COV-2 MPro.
• Figure 4 shows the enzymatic inhibitory activity of compound 296 on SARS-COV-2 MPro.
• Figure 5 shows the enzyme activity inhibitory activity of compound 398 on SARS-COV-2 MPro.
• Figure 6 shows the antiviral activity of some compounds of the present invention at the cell level.
• Figure 7 shows the antiviral activity of compound 398 at the cellular level.
• Figure 8 is the viral load test result of compound 398 antiviral experiment in vivo
• Figure 9 is the virus titer detection result of compound 398 antiviral experiment in vivo
• Figure 10 shows the results of immunohistochemical staining and histopathological staining of compound 398 in vivo antiviral experiments
• the raw materials and equipment used in the present invention are known products obtained by purchasing commercially available products.
• ketoamide derivatives shown in the above formula I include:
• Embodiment 1 prepares compound 1
• Step a Intermediate 1 (tert-butyl((2R,3S)-hydroxy-4-oxo-1-phenyl-4-(pyridin-2-ylmethyl)amino)butan-2-yl)carbamate esters).
• Step b Preparation of intermediate 2 ((2S,3R)-3-amino-2-hydroxy-4-phenyl-N-(pyridin-2-ylmethyl)butanamide hydrochloride).
• Step c Preparation of intermediate 3 (methyl (R)-2-(benzyloxy)propionate).
• Step d Preparation of intermediate 4 ((R)-2-(benzyloxy)propanoic acid).
• Embodiment 3 prepares compound 331
• Step a same as step a of Example 2;
• Step b same as step b of Example 2;
• Step c same as step c of Example 2;
• Step d same as step d of Example 2;
• Step f Compound 331 ((R)-3-((R)-2-((4-fluorophenyl)sulfonamido)propionamido)-2-oxo-4-phenyl-N-(pyridine -2-ylmethyl)butyramide).
• Embodiment 4 prepares compound 296
• Step a same as step a of Example 2;
• Step c same as step c of Example 2;
• Step d same as step d of Example 2;
• Step e Intermediate 5(4,4-difluoro-N-((R)-1-(((2R,3S)-3-hydroxy-4-oxo-1-phenyl-4-((pyridine -2-ylmethyl)amino)butan-2)-yl)amino)-1-oxopropan-2-yl)piperidine-1-carboxamide).
• Embodiment 5 prepares compound 313
• Step b same as step b of Example 2;
• Step d Intermediate 4(1-amino-N-((2R,3S)-3-hydroxy-4-oxo-1-phenyl-4-((pyridin-2-ylmethyl)amino)butan- Preparation of 2-yl)cyclobutane-1-carboxamide) hydrochloride.
• Step f Compound 313 ((4,4-difluorocyclohexyl)methyl(R)-(1-((3,4-dioxo-1-phenyl-4-((pyridin-2-ylmethyl base) amino) but-2-yl) carbamoyl) cyclobutyl) carbamate) synthesis.
• Embodiment 6 prepares compound 52
• Step a Preparation of intermediate 1 ((R)-methyl 2-amino-3-(4-fluorophenyl)propanoate hydrochloride).
• Step d Preparation of intermediate 4 (tert-butyl (R)-(1-(4-fluorophenyl)-3-oxopropan-2-yl)carbamate).
• Step e Preparation of intermediate 5 (((2R)-1-cyano-3-(4-fluorophenyl)-1-hydroxypropan-2-yl)carbamate tert-butyl ester).
• Step f Preparation of intermediate 6 ((3R)-3-amino-4-(4-fluorophenyl)-2-hydroxybutyrate hydrochloride).
• Step g Preparation of intermediate 7 ((3R)-3-amino-4-(4-fluorophenyl)-2-hydroxybutyric acid methyl ester hydrochloride).
• Step h same as step c of Example 1;
• Step j Preparation of intermediate 10 ((3R)-3-((R)-2-(benzyloxy)propionamido)-4-(4-fluorophenyl)-2-hydroxybutyric acid methyl ester) .
• Step k Preparation of intermediate 11 ((3R)-3-((R)-2-(benzyloxy)propionamido)-4-(4-fluorophenyl)-2-hydroxybutanoic acid).
• Step 1 Intermediate 12 ((3R)-3-((R)-2-(benzyloxy)propionamido)-N-((5-chloropyridin-2-yl)methyl)-4-( Preparation of 4-fluorophenyl)-2-hydroxybutanamide).
• Step a same as step a of Example 2;
• Step b same as step b of Example 2;
• Step c Intermediate 3 (methyl 3-(((2R,3S)-3-hydroxy-4-oxo-1-phenyl-4-((pyridin-2-ylmethyl)amino)butan-2 -yl)amino)-2,2-dimethyl-3-oxopropionate) preparation.
• Step d Intermediate 4 (3-((((2R,3S)-3-hydroxy-4-oxo-1-phenyl-4-((pyridin-2-ylmethyl)amino)butan-2- base) amino)-2,2-dimethyl-3-oxopropionic acid) preparation.
• Step e Intermediate 5(N 1 -((4,4-difluorocyclohexyl)methyl)-N 3 -((2R,3S)-3-hydroxy-4-oxo-1-phenyl-4 - Preparation of ((pyridin-2-ylmethyl)amino)butan-2-yl)-2,2-dimethylmalonamide).
• Embodiment 8 prepares compound 326
• Step a same as step a of Example 2;
• Step f Intermediate 6 ((2S,3R)-2-Hydroxy-3-(2-methyl-2-(4-phenyl-1H-pyrazol-1-yl)propionamido)-4-benzene Preparation of -N-(pyridin-2-ylmethyl)butyramide).
• Step a same as step a of Example 2;
• Step b same as step b of Example 2;
• Step d Preparation of intermediate 4 (O-benzyl-N-methylhydroxylamine).
• Step e Intermediate 5 ((2S,3R)-3-(3-(Benzyloxy)-3-methylureido)-2-hydroxy-4-phenyl-N-(pyridin-2-ylmethyl base) butanamide) preparation.
• Step f Product 58 ((R)-3-(3-(benzyloxy)-3-methylureido)-2-oxo-4-phenyl-N-(pyridin-2-ylmethyl) Butanamide) preparation.
• Embodiment 10 prepares compound 398
• Step a Intermediate 1 (tert-butyl((2R,3S)-hydroxy-4-oxo-1-phenyl-4-(pyridin-2-ylmethyl)amino)butan-2-yl)carbamate esters).
• Step b Preparation of intermediate 2 ((2S,3R)-3-amino-2-hydroxy-4-phenyl-N-(thiazol-2-ylmethyl)butanamide hydrochloride).
• Step c Intermediate 3 (tert-butyl((R)-1-(((2R,3S)-3-hydroxy-4-oxo-1-phenyl-4-((thiazol-2-ylmethyl )amino)but-2-yl)amino)-3-methoxy-1-oxopropan-2-yl)carbamate).
• Step d Intermediate 4 ((2S,3R)-3-((R)-2-amino-3-methoxypropionamido)-2-hydroxy-4-phenyl-N-(thiazole-2- Preparation of methyl) butanamide hydrochloride).
• Step e Intermediate 5(3,3-difluoro-N-((R)-1-(((2R,3S)-3-hydroxy-4-oxo-1-phenyl-4-((thiazole -2-ylmethyl)amino)butan-2-yl)amino)-3-methoxy-1-oxopropan-2-yl)cyclohexane-1-carboxamide).
• Step f Product 398 (N-((R)-1-(((R)-3,4-dioxo-1-phenyl-4-((thiazol-2-ylmethyl)amino)butan- Preparation of 2-yl)amino)-3-methoxy-1-oxopropan-2-yl)-3,3-difluorocyclohexane-1-carboxamide).
• Embodiment 11 prepares compound 490
• Step a same as step a of Example 10;
• Step b same as step b of Example 10;
• Step c Preparation of intermediate 3 (ethyl 1-(2,4,5-trifluorobenzyl)-1H-pyrazole-4-carboxylate).
• Step d Preparation of intermediate 4 (1-(2,4,5-trifluorobenzyl)-1H-pyrazole-4-carboxylic acid).
• Step e Intermediate 5 (N-((2R,3S)-3-hydroxy-4-oxo-1-phenyl-4-((thiazol-2-ylmethyl)amino)butan-2-yl) - Preparation of 1-(2,4,5-trifluorobenzyl)-1H-pyrazole-4-carboxamide).
• Embodiment 13 prepares compound 516
• Step a same as step a of Example 10;
• Step b same as step b of Example 10;
• Step c Preparation of intermediate 3 (ethyl 3-(hydroxyamino)-3-iminopropionate).
• Step d Preparation of intermediate 4 (ethyl 2-(5-(3,4-difluorophenyl)-1,2,4-oxadiazol-3-yl)acetate).
• Step e Preparation of intermediate 5 (2-(5-(3,4-difluorophenyl)-1,2,4-oxadiazol-3-yl)acetic acid).
• Step f Intermediate 6 ((2S,3R)-3-(2-(5-(3,4-difluorophenyl)-1,2,4-oxadiazol-3-yl)acetamido)- Preparation of 2-Hydroxy-4-phenyl-N-(thiazol-2-ylmethyl)butanamide).
• Step g Final product 516 ((R)-3-(2-(5-(3,4-difluorophenyl)-1,2,4-oxadiazol-3-yl)acetamido)-2- Preparation of oxo-4-phenyl-N-(thiazol-2-ylmethyl)butanamide).
• Step a same as step a of Example 10;
• Step d Preparation of intermediate 4 (ethyl 2-(3-(3-cyano-5-fluorophenyl)-2,5-dioxoimidazolin-1-yl)acetate).
• Step f Intermediate 6 ((2S,3R)-3-(2-(3-(3-cyano-5-fluorophenyl)-2,5-dioxoimidazolin-1-yl)acetamido )-2-Hydroxy-4-phenyl-N-(thiazol-2-ylmethyl)butyramide).
• Step f Final product 518 ((R)-3-(2-(3-(3-cyano-5-fluorophenyl)-2,5-dioxoimidazolin-1-yl)acetamido)- Preparation of 2-oxo-4-phenyl-N-(thiazol-2-ylmethyl)butanamide).
• Embodiment 15 prepares compound 532
• Step d Preparation of intermediate 4 (2-(4-(2-fluorophenyl)-1H-1,2,3-triazol-1-yl)acetic acid).
• Step e Intermediate 5 ((2S,3R)-3-(2-(4-(2-fluorophenyl)-1H-1,2,3-triazol-1-yl)acetamide)-2- Preparation of hydroxy-4-phenyl-N-(thiazol-2-ylmethyl)butanamide).
• Recombinant SARS-CoV-2 M pro (final concentration 750 nM) was mixed with serial dilutions of each compound in 25 ⁇ L assay buffer (20 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 2 mM DTT), and Incubate for 10 minutes. Initiate the reaction by adding 25 ⁇ L of fluorescent substrate (MCA-AVLQ ⁇ SGFR-Lys(Dnp)-Lys-NH 2 ) at a final concentration of 20 ⁇ M, and measure the fluorescent signal at 320 nm (excitation)/405 nm (emission) with a microplate reader .
• fluorescent substrate MCA-AVLQ ⁇ SGFR-Lys(Dnp)-Lys-NH 2
• Vmax of the responses to the addition of various concentrations of the compound was calculated versus the Vmax of the responses to the addition of DMSO and used to generate IC50 curves.
• IC50 values against SARS-CoV-2 Mpro were measured at 9 concentrations and 3 independent replicates. All experimental data were analyzed using GraphPad Prism software.
• the solution for intragastric administration and intravenous administration is prepared with DMSO/HS15/PEG400/NaCl (5/3/40/52, v/v/v).
• Administer the drug according to the dosage shown in Table 4 record the administration time, and collect about 0.20 mL of each sample through the jugular vein at the time point set above or other appropriate methods, anticoagulate with heparin sodium, and place it on ice after collection. superior. And centrifuge the plasma within 1 hour (centrifugation conditions: 6800g, 6 minutes, 2-8°C). Plasma samples were stored in a -80°C freezer until analysis. The grouping and blood collection time points are shown in Table 4, and there were 3 animals at each time point.
• HEK-293-hERG cells were subcultured to a suitable state, they were digested and separated with trypsin and stored in a centrifuge tube. After centrifugation, the supernatant was discarded, and the cells were resuspended with extracellular fluid for use. Before patch clamp recording, the cells Drop into the culture dish to ensure that the cells have a certain density and the cells are in a single separation state.
• hERG currents were recorded using the whole-cell patch clamp technique. Add the cell suspension to a small petri dish and place it on the stage of an inverted microscope. After the cells adhere to the wall, perfuse with extracellular fluid at a flow rate of 1-2 mL/min. The glass microelectrode is drawn by a microelectrode drawing machine in two steps. After filling the electrode inner liquid, its water resistance value is 2-5M ⁇ .
• K18-hACE2 transgenic mice (6-8 weeks old) were purchased from The Jackson Laboratory, and the use of animals complied with all relevant ethical regulations and was approved by the Committee on the Use of Live Animals in Teaching and Research of the University of Hong Kong.
• Female or male K18-hACE2 transgenic mice were inoculated intranasally (in) with 2000 PFU of SARS-CoV-2 Omicron (B.1.1.529) BA.2 mutant strain.
• mice were orally administered 150 mg/kg WSK-S02 compound 398 twice a day from 1 hpi on the day of infection to day 4 (4 dpi).
• mice were orally administered Compound 398 (150 mg/kg) or Compound 398 (150 mg/kg)/ritonavir (RTV, 10 mg/kg), Nirmatrelvir (150 mg/kg) or Nirmatrelvir (150 mg/kg) twice daily from 1 dpi /kg)/ritonavir (RTV, 10mg/kg) to 4dpi.
• Mice treated with vehicle (5%DMSO/3%Solutol HS-15/40%PEG400/normal saline) were used as a control group, and the survival of the mice was monitored every day during the test, and the mice were sacrificed at 4dpi, and the organs and tissues were Samples were taken for virological and histopathological analysis.
• mice were sacrificed when the K18-hACE2 transgenic mouse model infected with SARS-CoV-2 Omicron (B.1.1.529) BA.2 was treated to 4dpi, and the lung tissue samples of mice in each group were obtained.
• Transgenic mouse tissue samples were lysed with RLT buffer (Qiagen) and extracted with RNeasy Mini kit. After RNA extraction, use Transcriptor First Strand cDNA Synthesis Kit, QuantiNova SYBR Green RT-PCR Kit, or QuantiNova Probe RT-PCR Kit for RT-qPCR analysis.
• Vero E6-TMPRSS2 cells were seeded in 12-well plates 1 day before infection. The animals were sacrificed when the K18-hACE2 transgenic mouse model infected with SARS-CoV-2 Omicron (B.1.1.529) BA.2 was treated to 4dpi, and the lung tissue samples of mice in each group were obtained. The supernatants of harvested tissue samples were serially diluted and seeded into cells at 37°C for 1 hour. After seeding, cells were washed 3 times with PBS and mixed with 2% agarose/PBS and 2 ⁇ DMEM/2% FBS at a ratio of 1:1. Cells were fixed after 48 h and stained with 0.5% crystal violet in 25% ethanol/distilled water for 10 min for plaque quantification.
• the immunohistological staining test results for the SARS-CoV-2 nucleocapsid (N) protein showed ( Figure 10A) that viral antigens were most expressed in the lungs of mice in the vehicle control group (black arrows), This was followed by treatment with either Nirmatrelvir or Compound 398 alone, and the combination of Nirmatrelvir/RTV and Compound 398/RTV similarly restricted N protein expression to very low levels in the lung tissue of infected mice.
• the results of tissue H&E staining analysis (Fig. 10B) showed that the most prominent lung pathological feature in the vehicle control group was multifocal inflammatory infiltration in the alveolar septa, peribronchiolar area, and perivascular area. In contrast, sporadic inflammatory cell infiltration was occasionally found in the alveolar interstitium of mice treated with compound 398.
• Compound 398/RTV combined administration further improved lung tissue structure compared with monotherapy.
• mice Male ICR mice (6-8 weeks old, weighing 16-25g), or male Beagle dogs (1-2 years old, weighing 9-12kg), or male cynomolgus monkeys (6-7 years old, weighing 6-8kg) , respectively, were randomly divided into three groups, and a series of test compounds were administered by intragastric (p.o.) or intravenous (i.v.) according to the scheme in Table 10 below.
• intragastric p.o.
• i.v. intravenous
• the solution for intragastric administration and intravenous administration is prepared with DMSO/HS15/PEG400/NaCl (5/3/40/52, v/v/v).
• Administer the drug according to the dosage shown in Table 4 record the administration time, and collect about 0.20 mL of each sample through the jugular vein at the time point set above or other appropriate methods, anticoagulate with heparin sodium, and place it on ice after collection. superior. And centrifuge the plasma within 1 hour (centrifugation conditions: 6800g, 6 minutes, 2-8°C). Plasma samples were stored in a -80°C freezer until analysis. The grouping and blood collection time points are shown in Table 4, and there were 3 animals at each time point.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Molecular Biology (AREA)
• Virology (AREA)
• Biophysics (AREA)
• Genetics & Genomics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Biochemistry (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Priority Applications (3)

Applications Claiming Priority (2)

Publications (1)

Family

ID=87830006

Family Applications (1)

Country Status (5)

Cited By (2)

Citations (8)

Family Cites Families (11)

• 2023
  • 2023-02-15 EP EP23762735.1A patent/EP4488264A4/en active Pending
  • 2023-02-15 JP JP2023580943A patent/JP2025507472A/ja active Pending
  • 2023-02-15 WO PCT/CN2023/076078 patent/WO2023165334A1/zh not_active Ceased
  • 2023-02-15 US US18/723,545 patent/US20250064789A1/en active Pending
  • 2023-02-17 CN CN202310131329.0A patent/CN116693447B/zh active Active

Patent Citations (8)

Non-Patent Citations (8)

Also Published As

Similar Documents

Legal Events